Hydroxychloroquine
- PDF / 169,398 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 84 Downloads / 159 Views
1 S
Acute generalised exanthematous pustulosis following off-label use: case report A 39-year-old woman developed acute generalised exanthematous pustulosis (AGEP) during off-label treatment with hydroxychloroquine for COVID-19. The woman was admitted to a hospital in Tunisia on 31 March 2020 for COVID-19 management. Her diagnosis was confirmed after nasopharyngeal swab PCR examination. She started receiving off-label hydroxychloroquine 600 mg/day [route not stated]. She also received enoxaparin sodium [enoxaparin] and supplemental oxygen with a slight improvement in symptoms and arterial blood gas. Eighteen days following hydroxychloroquine initiation, she developed a pruritic eruption. Physical examination showed a cephalocaudal spread of erythematous and pustular plaques. Laboratory tests revealed leucocytosis, eosinophilia and neutrophilia. Based on clinical and histopathological examinations a diagnosis of AGEP was made. AGEP was attributed to hydroxychloroquine. The woman’s hydroxychloroquine therapy was stopped. Consequently, significant improvement was noted in skin lesions. Unfortunately, she died due to a massive pulmonary embolism associated with COVID-19. Litaiem N, et al. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. Dermatologic Therapy 33: No. 4, Jul-Aug 2020. Available 803507504 from: URL: http://doi.org/10.1111/dth.13565
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
